Macrocyclic fluorine substituted indole derivatives

US12152041B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Steven James Ferrara · Cambridge, US
• Michael H. Serrano-Wu · Cambridge, US
• Chris Lemke · Cambridge, US
• David McKinney · Cambridge, US
• Mark Fitzgerald · Cambridge, US
• Christopher G. Nasveschuk · Stoneham, US
• Kiel Lazarski · Cambridge, US
• Laura Furst · Cambridge, US
• Guo Ping Wei · Richmond, US
• Patrick R. McCarren · Cambridge, US
• Kai Thede · Leverkusen, DE
• Anne Mengel · Berlin, DE
• Clara Christ · Leverkusen, DE
• Joachim Kuhnke · Leverkusen, DE
• Sarah Anna Liesa Johannes · Düsseldorf, DE
• Philipp Buchgraber · Leverkusen, DE
• Ulrich Klar · Berlin, DE
• Ulrike Rauh · Leverkusen, DE
• Stefan Kaulfuss · Berlin, DE
• Amaury Ernesto Fernandez-Montalvan · Leverkusen, DE
• Nicolas Werbeck · Berlin, DE
• Ursula Mönning · Mölln, DE

Key dates

• Filing date: Mar 10, 2022
• Grant date: Nov 26, 2024
• Expiry date: Sep 24, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.